Inventor · disambiguated record
Ulrich Rodeck
Also filed as: RODECK ULRICH
11 granted patents·5 pending applications·220 citations·filing 1990–2022
90Inventor score
Top patents by PatentIndex Score
16 records- 0196US10357571B2Development of masked therapeutic antibodies to limit off-target effectsHOPE CITY·Filed 2015·Granted Jul 23, 2019·18 cites·8 claims
- 0294US8895702B2Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodiesWILLIAMS JOHN C·Filed 2012·Granted Nov 25, 2014·27 cites·4 claims
- 0388US5470571AMethod of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425WISTAR INST·Filed 1990·Granted Nov 28, 1995·86 cites·1 claims
- 0482US10689423B2CTLA4-binding protein peptide-linker masksHOPE CITY·Filed 2016·Granted Jun 23, 2020·2 cites·15 claims
- 0581US11311622B2Development of masked therapeutic antibodies to limit off-target effectsHOPE CITY·Filed 2019·Granted Apr 26, 2022·1 cites·5 claims
- 0679US5622835AWT1 monoclonal antibodiesWISTAR INST·Filed 1994·Granted Apr 22, 1997·41 cites·10 claims
- 0777US10414814B2Tumor-selective CTLA-4 antagonistsHOPE CITY·Filed 2015·Granted Sep 17, 2019·2 cites·5 claims
- 0876US2023085485A1Design and development of masked therapeutic antibodies to limit off-target effectsHOPE CITY·Filed 2022·Application pending·0 cites
- 0973US5633142AWT1 monoclonal antibodies and methods of use thereforWISTAR INST·Filed 1995·Granted May 27, 1997·43 cites·4 claims
- 1065US11279752B2Tumor-selective CTLA-4 antagonistsHOPE CITY·Filed 2019·Granted Mar 22, 2022·0 cites·10 claims
- 1163US11926652B2CTLA4-binding protein peptide-linker masksHOPE CITY·Filed 2020·Granted Mar 12, 2024·0 cites·20 claims
- 1262US2016152711A1Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodiesHOPE CITY·Filed 2014·Application pending·0 cites
- 1360US11186642B2Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodiesHOPE CITY·Filed 2017·Granted Nov 30, 2021·0 cites·9 claims
- 1457US2024325340A1Isoform specific agonists targeting akt kinaseUNIV JEFFERSON·Filed 2022·Application pending·0 cites
- 1552US2010189727A1Masking Ligands For Reversible Inhibition Of Multivalent CompoundsTEGOPHARM CORP·Filed 2009·Application pending·0 cites
- 1637US2011178279A1Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodiesWILLIAMS JOHN C·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →